Ivonescimab plus chemo for colorectal cancer without liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to other parts of the body but not to the liver.
- You have already had one type of chemotherapy as your first treatment, and it has stopped working or you cannot continue it.
- You are 18 years or older.
- You are in good enough health to walk and take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- You have adequate organ function, including blood counts, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab, which is a bispecific antibody that targets both PD-1 and VEGF. It is for people with metastatic colorectal cancer who have already tried standard treatments and may or may not have received immunotherapy before, depending on their tumor type.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a new drug called ivonescimab combined with chemotherapy for people whose colorectal cancer has spread only to the liver and cannot be surgically removed right away. The goal is to see if this combination can shrink the tumors enough to allow surgery or other treatments.
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
This trial compares two combinations of drugs for people with a certain type of advanced colorectal cancer that has progressed after initial treatment. It aims to see if one combination works better than the other, potentially offering a new option for second-line therapy.
This trial tests whether adding a new drug called ivonescimab to standard chemotherapy helps shrink advanced colon cancer before surgery. It may improve the chances of removing all the cancer and reduce the risk of it coming back.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.